Pulmonary Hypertension in the Intensive Care Unit (ICU) - Swiss Survey 1

ISRCTN	ISRCTN01751283
DOI	https://doi.org/10.1186/ISRCTN01751283
Protocol serial number	N/A
Sponsor	Swiss Society of Pulmonary Hypertension (Switzerland)
Funders	Swiss Society of Intensive Care Medicine (Switzerland), Actelion Pharma Schweiz AG (Switzerland), Lung League Ticino (Switzerland)

Submission date: 06/09/2010
Registration date: 28/10/2010
Last edited: 28/10/2010

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Circulatory System

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Urs Wenger
Scientific

University Hospital Zürich
Rämistrasse 100
Zürich
8091
Switzerland

Study information

Primary study design	Observational
Study design	Prospective multicentre study
Secondary study design	Non randomised controlled trial
Study type	Participant information sheet
Scientific title	A prospective multicentre study to investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension in the Intensive Care Unit (ICU)
Study acronym	PHICUSS1
Study objectives	To investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension (PH) of any cause in the setting of surgical, medical or interdisciplinary Intensive Care Units (ICUs) of primary, secondary and tertiary Swiss hospitals.
Ethics approval(s)	Ethics approval was not required for this study.
Health condition(s) or problem(s) studied	Pulmonary hypertension
Intervention	The current characteristics, local facilities, diagnostic and therapeutic attitude against PH of the participating ICUs are assessed prior to study beginning by a questionnaire (hospital form). During the study period all consecutive patients admitted to ICU for any reason are screened for presence or suspicion of PH. If PH is present or suspected the most probable causes, diagnostic and therapeutic attitude, clinical, laboratory, haemodynamic data (if measured) and 30 days survival will be assessed by a questionnaire (patient form). Participating centres are asked to complete the hospital form only once, before study begin. Thereafter, during the enrolment period all patients admitted to the participating ICU are screened by use of the patient from. Only if PH is present, suspected or disclosed at ICU admission, or if risk factors for PH were present, additional information will be requested. Data collection will be performed online using an electronic form of the data collection sheet.
Intervention type	Other
Primary outcome measure(s)	Prevalence of PH of any cause in the setting of surgical, medical or interdisciplinary ICUs. During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.
Key secondary outcome measure(s)	1. Causes of PH in the ICU setting 2. Diagnostic and therapeutic approach to PH by Swiss ICU physicians 3. 30 day outcome of patients admitted to ICU with suspected or confirmed PH During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.
Completion date	30/09/2009

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	All
Target sample size at registration	1000
Key inclusion criteria	All consecutive patients (no age limit or gender restrictions) admitted to ICU for any reason
Key exclusion criteria	Does not meet inclusion criteria
Date of first enrolment	01/09/2009
Date of final enrolment	30/09/2009

Locations

Countries of recruitment

Switzerland

Study participating centre

University Hospital Zürich

Zürich
8091
Switzerland

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes